Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
